Healthcare / Drug Manufacturers - General
Exclusive insider sentiment analysis for the Drug Manufacturers - General sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 20:29 | 2026-04-01 | BMY | BRISTOL MYERS SQUIBB CO | Elkins David V | Officer; EVP, Chief Financial Officer | Drug Manufacturers - General | SALE | $61.67 | 30,000 | $1,850,016 | 159,248 | -15.9% |
| 2026-04-01 11:31 | 2026-03-31 | NSRX | Nasus Pharma Ltd | Teleman Dan Benjamin | Director, Officer; Chief Executive Officer | Drug Manufacturers - General | BUY | $2.04 | 15,000 | $30,600 | 21,246 | +240.2% |
| 2026-03-30 21:59 | 2026-03-27 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | SALE | $136.82 | 10,000 | $1,368,162 | 642,567 | -1.5% |
| 2026-03-17 22:56 | 2026-03-16 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Comm & Corp Aff Officer | Drug Manufacturers - General | SALE | $144.23 | 3,000 | $432,690 | 131,779 | -2.2% |
| 2026-03-17 22:14 | 2026-03-16 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer; Chief Financial Officer | Drug Manufacturers - General | SALE | $144.23 | 3,000 | $432,690 | 179,191 | -1.6% |
| 2026-03-07 01:05 | 2026-03-04 | ABBV | AbbVie Inc. | Purdue David Ryan | Officer; SVP, Controller | Drug Manufacturers - General | SALE | $233.56 | 5,230 | $1,221,519 | 2,654 | -66.3% |
| 2026-03-04 00:21 | 2026-02-27 | JNJ | JOHNSON & JOHNSON | Decker Robert J | Officer; VP Corporate Controller | Drug Manufacturers - General | OPT+S | $247.87 | 4,075 | $1,010,070 | 23,682 | -14.7% |
| 2026-03-04 02:10 | 2026-03-02 | ABBV | AbbVie Inc. | Siatis Perry C | Officer; EVP, GC AND SECRETARY | Drug Manufacturers - General | SALE | $234.39 | 18,668 | $4,375,550 | 4,619 | -80.2% |
| 2026-03-03 00:46 | 2026-02-27 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | SALE | $144.79 | 10,000 | $1,447,859 | 642,308 | -1.5% |
| 2026-03-03 03:20 | 2026-02-26 | AMGN | Amgen Inc. | Santos Esteban | Officer; EVP, Operations | Drug Manufacturers - General | OPT+S | $379.12 | 54,792 | $20,772,595 | 76,618 | -41.7% |
| 2026-02-28 01:00 | 2026-02-25 | ABBV | AbbVie Inc. | Siatis Perry C | Officer; EVP, GC AND SECRETARY | Drug Manufacturers - General | OPT+S | $230.00 | 22,381 | $5,147,630 | 38,137 | -37.0% |
| 2026-02-24 01:20 | 2026-02-20 | JNJ | JOHNSON & JOHNSON | Schmid Timothy | Officer; EVP, WW Chair, MedTech | Drug Manufacturers - General | SALE | $245.66 | 1,322 | $324,763 | 25,447 | -4.9% |
| 2026-02-21 03:43 | 2026-02-19 | AMGN | Amgen Inc. | Busch Matthew C. | Officer; VP, Finance & CAO | Drug Manufacturers - General | SALE | $375.79 | 1,000 | $375,790 | 3,423 | -22.6% |
| 2026-02-19 01:22 | 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Comm & Corp Aff Officer | Drug Manufacturers - General | OPT+S | $154.44 | 28,000 | $4,324,228 | 120,288 | -18.9% |
| 2026-02-19 05:11 | 2026-02-17 | JNJ | JOHNSON & JOHNSON | Broadhurst Vanessa | Officer; EVP, Global Corp Affairs | Drug Manufacturers - General | OPT+S | $243.39 | 6,197 | $1,508,288 | 23,003 | -21.2% |
| 2026-02-19 05:11 | 2026-02-18 | JNJ | JOHNSON & JOHNSON | Schmid Timothy | Officer; EVP, WW Chair, MedTech | Drug Manufacturers - General | OPT+S | $244.33 | 22,623 | $5,527,507 | 26,769 | -45.8% |
| 2026-02-19 05:12 | 2026-02-17 | JNJ | JOHNSON & JOHNSON | REED JOHN C | Officer; EVP, Innovative Medicine, R&D | Drug Manufacturers - General | OPT+S | $243.00 | 53,931 | $13,105,233 | 10,658 | -83.5% |
| 2026-02-19 05:12 | 2026-02-17 | JNJ | JOHNSON & JOHNSON | Wolk Joseph J | Officer; Exec VP, CFO | Drug Manufacturers - General | OPT+S | $242.80 | 89,654 | $21,767,830 | 14,000 | -86.5% |
| 2026-02-19 05:12 | 2026-02-13 | JNJ | JOHNSON & JOHNSON | Swanson James D. | Officer; EVP, CIO | Drug Manufacturers - General | OPT+S | $243.39 | 62,080 | $15,109,757 | 25,698 | -70.7% |
| 2026-02-19 01:11 | 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer; Chief Financial Officer | Drug Manufacturers - General | SALE | $154.43 | 3,000 | $463,290 | 167,779 | -1.8% |
| 2026-02-18 04:16 | 2026-02-12 | BIIB | BIOGEN INC. | Murphy Nicole | Officer; Head of Pharm Ops and Tech | Drug Manufacturers - General | BUY | $195.04 | 3 | $585 | 19,611 | +0.0% |
| 2026-02-13 00:02 | 2026-02-12 | MRK | Merck & Co., Inc. | Guindo Chirfi | Officer; Chief Marketing Officer | Drug Manufacturers - General | SALE | $121.46 | 10,000 | $1,214,562 | 60,615 | -14.2% |
| 2026-02-11 00:04 | 2026-02-10 | MRK | Merck & Co., Inc. | Li Dean Y | Officer; Executive VP & President, MRL | Drug Manufacturers - General | SALE | $117.52 | 10,235 | $1,202,844 | 92,035 | -10.0% |
| 2026-02-11 01:05 | 2026-02-09 | BIIB | BIOGEN INC. | Singhal Priya | Officer; Head of Development | Drug Manufacturers - General | OPT+S | $199.83 | 2,660 | $531,548 | 8,043 | -24.9% |
| 2026-02-10 00:01 | 2026-02-09 | MRK | Merck & Co., Inc. | Zachary Jennifer | Officer; EVP, General Counsel | Drug Manufacturers - General | OPT+S | $119.15 | 121,573 | $14,485,690 | 68,916 | -63.8% |
| 2026-02-10 00:04 | 2026-02-09 | MRK | Merck & Co., Inc. | Guindo Chirfi | Officer; Chief Marketing Officer | Drug Manufacturers - General | SALE | $118.41 | 10,000 | $1,184,101 | 70,615 | -12.4% |
| 2026-02-07 00:18 | 2026-02-04 | MRK | Merck & Co., Inc. | Smart Dalton E. III | Officer; SVP Fin. - Global Controller | Drug Manufacturers - General | OPT+S | $119.68 | 6,400 | $765,920 | 8,205 | -43.8% |
| 2026-02-07 00:15 | 2026-02-06 | MRK | Merck & Co., Inc. | Oosthuizen Johannes Jacobus | Officer; President, U.S. Market | Drug Manufacturers - General | SALE | $121.87 | 15,000 | $1,827,992 | 21,197 | -41.4% |
| 2026-02-07 00:13 | 2026-02-04 | MRK | Merck & Co., Inc. | Litchfield Caroline | Officer; EVP & CFO | Drug Manufacturers - General | OPT+S | $119.61 | 41,997 | $5,023,312 | 90,192 | -31.8% |
| 2026-02-07 00:12 | 2026-02-04 | MRK | Merck & Co., Inc. | Li Dean Y | Officer; Executive VP & President, MRL | Drug Manufacturers - General | OPT+S | $118.77 | 15,087 | $1,791,824 | 102,270 | -12.9% |
| 2026-02-07 00:20 | 2026-02-06 | MRK | Merck & Co., Inc. | Williams David Michael | Officer; EVP,Chief Info&Digital Officer | Drug Manufacturers - General | OPT+S | $121.91 | 5,000 | $609,525 | 30,838 | -14.0% |
| 2026-02-07 00:10 | 2026-02-05 | MRK | Merck & Co., Inc. | Guindo Chirfi | Officer; Chief Marketing Officer | Drug Manufacturers - General | SALE | $121.88 | 20,000 | $2,437,676 | 80,615 | -19.9% |
| 2026-02-07 00:22 | 2026-02-05 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | OPT+S | $150.00 | 115,640 | $17,346,000 | 613,912 | -15.9% |
| 2026-02-07 00:08 | 2026-02-06 | MRK | Merck & Co., Inc. | DeLuca Richard R. | Officer; EVP&Pres, Merck Animal Heallth | Drug Manufacturers - General | SALE | $120.92 | 37,685 | $4,557,025 | 160,174 | -19.0% |
| 2026-02-07 00:05 | 2026-02-04 | MRK | Merck & Co., Inc. | Davis Robert M | Director, Officer; Chairman, CEO & President | Drug Manufacturers - General | SALE | $118.04 | 47,434 | $5,599,328 | 443,602 | -9.7% |
| 2026-02-04 01:17 | 2026-02-02 | BIIB | BIOGEN INC. | Singhal Priya | Officer; Head of Development | Drug Manufacturers - General | OPT+S | $179.30 | 748 | $134,116 | 6,271 | -10.7% |
| 2026-01-30 01:23 | 2026-01-28 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | SALE | $139.89 | 10,000 | $1,398,911 | 556,698 | -1.8% |
| 2026-01-29 02:07 | 2026-01-26 | JNJ | JOHNSON & JOHNSON | Duato Joaquin | Director, Officer; CEO and Chairman of the Board | Drug Manufacturers - General | SALE | $221.23 | 100,000 | $22,122,890 | 30,852 | -76.4% |
| 2026-01-27 03:29 | 2026-01-23 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | OPT+S | $135.00 | 115,640 | $15,611,400 | 566,698 | -16.9% |
| 2026-01-22 00:26 | 2026-01-20 | GILD | GILEAD SCIENCES, INC. | Bluestone Jeffrey | Director | Drug Manufacturers - General | OPT+S | $123.50 | 5,000 | $617,500 | 8,920 | -35.9% |
| 2026-01-17 02:10 | 2026-01-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Commercial Officer | Drug Manufacturers - General | SALE | $124.31 | 3,000 | $372,930 | 103,221 | -2.8% |
| 2026-01-17 02:18 | 2026-01-15 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer; Chief Financial Officer | Drug Manufacturers - General | SALE | $124.31 | 3,000 | $372,930 | 150,503 | -2.0% |
| 2026-01-09 00:00 | 2026-01-07 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | Drug Manufacturers - General | SALE | $1,103.48 | 292,148 | $322,380,731 | 91,896,978 | -0.3% |
| 2026-01-07 00:00 | 2026-01-05 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | Drug Manufacturers - General | SALE | $1,085.01 | 1,390 | $1,508,165 | 92,189,126 | 0.0% |
| 2025-12-31 00:00 | 2025-12-29 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | Drug Manufacturers - General | SALE | $1,085.04 | 3,593 | $3,898,531 | 92,190,516 | 0.0% |
| 2025-12-31 04:24 | 2025-12-26 | SCLX | Scilex Holding Co | Scilex Holding Co | 10% owner | Drug Manufacturers - General | SALE | $0.62 | 20,657,300 | $12,772,409 | 244,445,260 | -7.8% |
| 2025-12-31 00:23 | 2025-12-29 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | SALE | $124.83 | 10,000 | $1,248,272 | 566,698 | -1.7% |
| 2025-12-30 00:05 | 2025-12-24 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | Drug Manufacturers - General | SALE | $1,085.17 | 2,629 | $2,852,920 | 92,194,109 | 0.0% |
| 2025-12-30 00:00 | 2025-12-23 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | Drug Manufacturers - General | SALE | $1,085.04 | 240 | $260,409 | 92,196,738 | 0.0% |
| 2025-12-17 02:12 | 2025-12-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Commercial Officer | Drug Manufacturers - General | SALE | $122.00 | 3,000 | $366,000 | 106,221 | -2.7% |
Strategic Analysis
Analyzing insider transactions within the Drug Manufacturers - General sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.